About OyaGen
OyaGen is a Healthcare company based in Rochester (United States) founded in 2003 by Harold Smith. RNADNA editing enzymes are developed to halt HIV replication. It operates on a Professional Services, Licensing Model, and HealthTech model. OyaGen has raised $2.77 million across 13 funding rounds from investors including HHS. OyaGen offers products and services including HIV Antiretroviral Compound, Ebola Antiviral Compound, COVID-19 Antiviral Compound, Oncology Therapeutics, and Drug Discovery Services. Its focus areas include Biotechnology and Drug Discovery. Its legal entity is OyaGen, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
OyaGen is focused on preclinical drug discovery and development, targeting novel therapeutic indications for infectious diseases such as HIV, Ebola, and COVID-19, as well as cancer. Solutions are developed through identification and validation of lead compounds, which are IND-enabled for licensing or partnering with industry leaders for clinical development. Services are also offered on a fee-for-service basis, supporting academia and industry with assay development, screening, and mechanistic studies. The companys expertise is leveraged in high-throughput screening to address multiple diseases, including underserved therapeutic areas.
- Headquarters Rochester, United States
- Founders Harold Smith
- SectorsHealthcare
- Phone•••• ••••
- Website oyageninc.com
- Social LinkedIn
- Legal Name Oyagen, Inc.
- Total Equity Funding$2.77M (USD)
in 13 rounds
- Latest Funding Round$597K (USD), Grant
Aug 2023
- Investors
Products & Services of OyaGen
OyaGen offers a comprehensive portfolio of products and services, including HIV Antiretroviral Compound, Ebola Antiviral Compound, COVID-19 Antiviral Compound, Oncology Therapeutics, and Drug Discovery Services.
Lead compound disables HIV Vif protein for immunity.
Compound blocks Ebola VP40 protein from assembling virions.
Broadly neutralizing compound targets multiple Coronavirus variants effectively.
Therapeutics target mechanisms for tumor growth and progression.
Fee-for-service drug discovery and assay development offered.
Funding Insights of OyaGen
OyaGen has successfully raised a total of $2.77M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $597 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.77M
- Total Rounds 13
- Last Round Grant — $597,000
- First Round $1.03M
(Sep 2009)
- Investors Count 1
Latest 10 of 13 funding rounds of OyaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $597,000 | Grant | – | – | |
| Jul 2020 | $572,862 | Grant | – | – | |
| Aug 2018 | $600,000 | Grant | – | – | |
| Dec 2017 | $345,000 | Debt – Conventional | – | – | – |
| Aug 2016 | $604,517 | Grant | – | – | |
| Apr 2015 | $1.77M | Grant | – | – | |
| Sep 2013 | $1.39M | Grant | – | – | |
| Oct 2012 | $1.74M | Seed | – | – | – |
| Jun 2011 | $462,000 | Grant | – | – | |
| May 2011 | $462,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in OyaGen
OyaGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for OyaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OyaGen
1 people are tracked at OyaGen (1 in leadership).
| Name | Role | Group |
|---|---|---|
Harold Smith | Founder & President | Leadership |
Complete people profiles for OyaGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OyaGen
3 dated milestones of OyaGen across 20 years, from founding to its latest funding, stage changes and deals.
- Founded OyaGen is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Grant, of $597K.
Competitors of OyaGen
OyaGen has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of OyaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OyaGen
The website of OyaGen (oyageninc.com) receives about 2K visits a month.
- Monthly visits2K
▲ 28.9% vs previous month
Websites whose visitors overlap most with OyaGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| zytex.com | 100% | 1.3K | #9,998,407 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as OyaGen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oyagen
Complete news archive for OyaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OyaGen
OyaGen was founded in 2003 and raised its 1st funding round 6 years after it was founded.
OyaGen is headquartered in Rochester, United States.
OyaGen is a funded company, having raised a total of $2.77M across 13 funding rounds to date. The company's 1st funding round was a Grant of $462K, raised on Sep 2009.
OyaGen is focused on preclinical drug discovery and development, targeting novel therapeutic indications for infectious diseases such as HIV, Ebola, and COVID-19, as well as cancer. Solutions are developed through identification and validation of lead compounds, which are IND-enabled for licensing or partnering with industry leaders for clinical development. Services are also offered on a fee-for-service basis, supporting academia and industry with assay development, screening, and mechanistic studies. The companys expertise is leveraged in high-throughput screening to address multiple diseases, including underserved therapeutic areas.
OyaGen's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
OyaGen offers HIV Antiretroviral Compound, Ebola Antiviral Compound, COVID-19 Antiviral Compound, Oncology Therapeutics, and Drug Discovery Services.
OyaGen has 1 investor. Key investors include HHS.
OyaGen operates through Oyagen, Inc..